Circulation. 2002;106:1610-1613
Published online before print September 16, 2002, doi: 10.1161/01.CIR.0000034447.02535.D5
Published online before print September 16, 2002, doi: 10.1161/01.CIR.0000034447.02535.D5
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2002;106:1610.)
© 2002 American Heart Association, Inc.
Brief Rapid Communications |
Persistent Inhibition of Neointimal Hyperplasia After Sirolimus-Eluting Stent Implantation
Long-Term (Up to 2 Years) Clinical, Angiographic, and Intravascular Ultrasound Follow-Up
From Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands (M.D., P.W.S., D.P.F., K.T., E.R., J.V., P.C.S., W.J.v.d.G., M.v.d.B., P.d.F.); and Brigham and Women‘s Hospital, Boston, Mass (J.J.P.).
Correspondence to Prof PW Serruys, MD, PhD, Thoraxcenter, Bd-408, University Hospital Dijkzigt, Dr. Molewaterplein-40, 3015 GD Rotterdam, The Netherlands. E-mail Serruys{at}card.azr.nl
Background— Early results of sirolimus-eluting stent implantation showed a nearly complete abolition of neointimal hyperplasia. The question remains, however, whether the early promising results will still be evident at long-term follow-up. The objective of our study was to evaluate the efficiency of sirolimus-eluting stent implantation for up to 2 years of follow-up.
Methods and Results— Fifteen patients with de novo coronary artery disease were treated with 18-mm sirolimus-eluting Bx-Velocity stents (Cordis) loaded with 140 µg sirolimus/cm2 metal surface area in a slow release formulation. Quantitative angiography (QCA) and intravascular ultrasound (IVUS) were performed according to standard protocol. Sirolimus-eluting stent implantation was successful in all 15 patients. During the in-hospital course, 1 patient died of cerebral hemorrhage after periprocedural administration of abciximab, and 1 patient underwent repeat stenting after 2 hours because of edge dissection that led to acute occlusion. Through 6 months and up to 2 years of follow-up, no additional events occurred. QCA analysis revealed no significant change in stent minimal lumen diameter or percent diameter stenosis, and 3-dimensional IVUS showed no significant deterioration in lumen volume. In 2 patients, additional stenting was performed because of significant lesion progression remote from the sirolimus-eluting stent.
Conclusion— Sirolimus-eluting stents showed persistent inhibition of neointimal hyperplasia for up to 2 years of follow-up.
Key Words: stents • restenosis • ultrasonics • drugs
This article has been cited by other articles:
 |
|
 |
|
  M. Awata, J.-i. Kotani, M. Uematsu, T. Morozumi, T. Watanabe, T. Onishi, O. Iida, F. Sera, S. Nanto, M. Hori, et al. Serial Angioscopic Evidence of Incomplete Neointimal Coverage After Sirolimus-Eluting Stent Implantation: Comparison With Bare-Metal Stents Circulation, August 21, 2007; 116(8): 910 - 916. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A N Seale, P E F Daubeney, A G Magee, and M L Rigby Pulmonary vein stenosis: initial experience with cutting balloon angioplasty Heart, June 1, 2006; 92(6): 815 - 820. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. T.L. Ong, R. T. van Domburg, J. Aoki, K. Sonnenschein, P. A. Lemos, and P. W. Serruys Sirolimus-Eluting Stents Remain Superior to Bare-Metal Stents at Two Years: Medium-Term Results From the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) Registry J. Am. Coll. Cardiol., April 4, 2006; 47(7): 1356 - 1360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Alvarez Jr and N. K. Kapur Drug Eluting Stent Technology: A Paradigm Shift in the Treatment and Prevention of Restenosis Journal of Pharmacy Practice, December 1, 2005; 18(6): 461 - 478. [Abstract] [PDF]
|
|
|
|
|
|
G Sianos, A Hoye, F Saia, W van der Giessen, P Lemos, P J de Feyter, P C Levendag, R van Domburg, and P W Serruys Long term outcome after intracoronary {beta} radiation therapy Heart, July 1, 2005; 91(7): 942 - 947. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Fajadet, M.-C. Morice, C. Bode, P. Barragan, P. W. Serruys, W. Wijns, C. R. Constantini, J.-L. Guermonprez, H. Eltchaninoff, D. Blanchard, et al. Maintenance of Long-Term Clinical Benefit With Sirolimus-Eluting Coronary Stents: Three-Year Results of the RAVEL Trial Circulation, March 1, 2005; 111(8): 1040 - 1044. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Lindenfeld, G. G. Miller, S. F. Shakar, R. Zolty, B. D. Lowes, E. E. Wolfel, L. Mestroni, R. L. Page II, and J. Kobashigawa Drug Therapy in the Heart Transplant Recipient: Part II: Immunosuppressive Drugs Circulation, December 21, 2004; 110(25): 3858 - 3865. [Full Text] [PDF]
|
|
|
|
|
|
J. J. Popma, M. B. Leon, J. W. Moses, D. R. Holmes Jr, N. Cox, M. Fitzpatrick, J. Douglas, C. Lambert, M. Mooney, S. Yakubov, et al. Quantitative Assessment of Angiographic Restenosis After Sirolimus-Eluting Stent Implantation in Native Coronary Arteries Circulation, December 21, 2004; 110(25): 3773 - 3780. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Murphy, A. J. Bryan, and G. D. Angelini Hybrid Coronary Revascularization in the Era of Drug-Eluting Stents Ann. Thorac. Surg., November 1, 2004; 78(5): 1861 - 1867. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Waksman, A. E. Ajani, A. D. Pichard, R. Torguson, E. Pinnow, D. Canos, L. F. Satler, K. M. Kent, P. Kuchulakanti, C. Pappas, et al. Oral rapamycin to inhibit restenosis after stenting of de novo coronary lesions: The Oral Rapamune to Inhibit Restenosis (ORBIT) study J. Am. Coll. Cardiol., October 6, 2004; 44(7): 1386 - 1392. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F Saia, P A Lemos, C A Arampatzis, A Hoye, M Degertekin, K Tanabe, G Sianos, P C Smits, W J van der Giessen, P J de Feyter, et al. Routine sirolimus eluting stent implantation for unselected in-stent restenosis: insights from the rapamycin eluting stent evaluated at Rotterdam cardiology hospital (RESEARCH) registry Heart, October 1, 2004; 90(10): 1183 - 1188. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Di Mario and G Mikhail Treating multivessel disease in the era of coated stents: introduction Heart, September 1, 2004; 90(9): 989 - 989. [Full Text] [PDF]
|
|
|
|
|
|
P W Serruys, P A Lemos, and B A van Hout Sirolimus eluting stent implantation for patients with multivessel disease: rationale for the arterial revascularisation therapies study part II (ARTS II) Heart, September 1, 2004; 90(9): 995 - 998. [Full Text] [PDF]
|
|
|
|
 |
|
 F. Vogt, A. Stein, G. Rettemeier, N. Krott, R. Hoffmann, J. v. Dahl, A.-K. Bosserhoff, W. Michaeli, P. Hanrath, C. Weber, et al. Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent Eur. Heart J., August 1, 2004; 25(15): 1330 - 1340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Hoye, K. Tanabe, P. A. Lemos, J. Aoki, F. Saia, C. Arampatzis, M. Degertekin, S. H. Hofma, G. Sianos, E. McFadden, et al. Significant reduction in restenosis after the use of sirolimus-eluting stents in the treatment of chronic total occlusions J. Am. Coll. Cardiol., June 2, 2004; 43(11): 1954 - 1958. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. D. Powell, C. S. Rihal, M. R. Bell, K. J. Zehr, and D. R. Holmes Jr Anticipated Impact of Drug-Eluting Stents on Referral Patterns for Coronary Artery Bypass Graft Surgery: A Population-Based Angiographic Analysis Mayo Clin. Proc., June 1, 2004; 79(6): 769 - 772. [Abstract] [PDF]
|
|
|
|
|
|
P. M. Mourani, P. J. Garl, J. M. Wenzlau, T. C. Carpenter, K. R. Stenmark, and M. C.M. Weiser-Evans Unique, Highly Proliferative Growth Phenotype Expressed by Embryonic and Neointimal Smooth Muscle Cells Is Driven by Constitutive Akt, mTOR, and p70S6K Signaling and Is Actively Repressed by PTEN Circulation, March 16, 2004; 109(10): 1299 - 1306. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Curcio, D. Torella, G. Cuda, C. Coppola, M. C. Faniello, F. Achille, V. G. Russo, M. Chiariello, and C. Indolfi Effect of stent coating alone on in vitro vascular smooth muscle cell proliferation and apoptosis Am J Physiol Heart Circ Physiol, March 1, 2004; 286(3): H902 - H908. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. W. Serruys, M. Degertekin, K. Tanabe, M. E. Russell, G. Guagliumi, J. Webb, J. Hamburger, W. Rutsch, C. Kaiser, R. Whitbourn, et al. Vascular Responses at Proximal and Distal Edges of Paclitaxel-Eluting Stents: Serial Intravascular Ultrasound Analysis From the TAXUS II Trial Circulation, February 10, 2004; 109(5): 627 - 633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. A. Lemos, P. W. Serruys, R. T. van Domburg, F. Saia, C. A. Arampatzis, A. Hoye, M. Degertekin, K. Tanabe, J. Daemen, T. K.K. Liu, et al. Unrestricted Utilization of Sirolimus-Eluting Stents Compared With Conventional Bare Stent Implantation in the "Real World": The Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) Registry Circulation, January 20, 2004; 109(2): 190 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Degertekin, P. A. Lemos, C. H. Lee, K. Tanabe, J.E. Sousa, A. Abizaid, E. Regar, G. Sianos, W. J. van der Giessen, P. J. de Feyter, et al. Intravascular ultrasound evaluation after sirolimus eluting stent implantation for de novo and in-stent restenosis lesions Eur. Heart J., January 1, 2004; 25(1): 32 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V Bhatia, R Bhatia, and M Dhindsa Drug-eluting stents: new era and new concerns Postgrad. Med. J., January 1, 2004; 80(939): 13 - 18. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Saia, P. A. Lemos, C.-H. Lee, C. A. Arampatzis, A. Hoye, M. Degertekin, K. Tanabe, G. Sianos, P. C. Smits, E. McFadden, et al. Sirolimus-Eluting Stent Implantation in ST-Elevation Acute Myocardial Infarction: A Clinical and Angiographic Study Circulation, October 21, 2003; 108(16): 1927 - 1929. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. R. Edelman and H. D. Danenberg Rapamycin for Cardiac Transplant Rejection and Vasculopathy: One Stone, Two Birds? Circulation, July 8, 2003; 108(1): 6 - 8. [Full Text] [PDF]
|
|
|
|
|
|
P. A. Lemos, P. W. Serruys, and J. E. Sousa Drug-Eluting Stents: Cost Versus Clinical Benefit Circulation, June 24, 2003; 107(24): 3003 - 3007. [Full Text] [PDF]
|
|
|
|
|
|
W. W. O'Neill and M. B. Leon Drug-Eluting Stents: Costs Versus Clinical Benefit Circulation, June 24, 2003; 107(24): 3008 - 3011. [Full Text] [PDF]
|
|
|
|
|
|
P. A. Lemos, C.-h. Lee, M. Degertekin, F. Saia, K. Tanabe, C. A. Arampatzis, A. Hoye, M. van Duuren, G. Sianos, P. C. Smits, et al. Early outcome after sirolimus-eluting stent implantation in patients with acute coronary syndromes: Insights from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry J. Am. Coll. Cardiol., June 4, 2003; 41(11): 2093 - 2099. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. J. Paszkowiak and A. Dardik Arterial Wall Shear Stress: Observations from the Bench to the Bedside Vascular and Endovascular Surgery, January 1, 2003; 37(1): 47 - 57. [Abstract] [PDF]
|
|
|
|
 |
|
 S. E. Levy and J. A.S. Muldowney 3rd Microarray Analysis of Neointima: Flowing Toward a Clear Future Arterioscler. Thromb. Vasc. Biol., December 1, 2002; 22(12): 1946 - 1947. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Mozes and P. Gloviczki Adjuvant Therapy in Lower Extremity Revascularization: Prevention of Early and Intermediate Failures Perspectives in Vascular Surgery and Endovascular Therapy, January 1, 2002; 15(2): 161 - 180. [Abstract] [PDF]
|
|